标题/作者	年份
mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy T Tian, X Li, J Zhang International journal of molecular sciences 20 (3), 755	2019
Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis J Yi, J Zhu, J Wu, CB Thompson, X Jiang Proceedings of the National Academy of Sciences 117 (49), 31189-31197	2020
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention LM Butler, Y Perone, J Dehairs, LE Lupien, V de Laat, A Talebi, M Loda, ... Advanced drug delivery reviews 159, 245-293	2020
The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling BY Shorning, MS Dass, MJ Smalley, HB Pearson International Journal of Molecular Sciences 21 (12), 4507	2020
Senescent cells in cancer therapy: friends or foes? B Wang, J Kohli, M Demaria Trends in cancer 6 (10), 838-857	2020
Recent advances in prostate cancer treatment and drug discovery E Nevedomskaya, SJ Baumgart, B Haendler International journal of molecular sciences 19 (5), 1359	2018
Mechanisms of PTEN loss in cancer: It’s all about diversity V Álvarez-Garcia, Y Tawil, HM Wise, NR Leslie Seminars in cancer biology 59, 66-79	2019
Cancer overdiagnosis: a biological challenge and clinical dilemma S Srivastava, EJ Koay, AD Borowsky, AM De Marzo, S Ghosh, PD Wagner, ... Nature Reviews Cancer 19 (6), 349-358	2019
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy D Tewari, P Patni, A Bishayee, AN Sah, A Bishayee Seminars in cancer biology 80, 1-17	2022
Radiogenomics: bridging imaging and genomics Z Bodalal, S Trebeschi, TDL Nguyen-Kim, W Schats, R Beets-Tan Abdominal radiology 44 (6), 1960-1984	2019
Genomic and phenotypic heterogeneity in prostate cancer MC Haffner, W Zwart, MP Roudier, LD True, WG Nelson, JI Epstein, ... Nature Reviews Urology 18 (2), 79-92	2021
Molecular biomarkers in localized prostate cancer: ASCO guideline SE Eggener, RB Rumble, AJ Armstrong, TM Morgan, T Crispino, ... Journal of Clinical Oncology 38 (13), 1474-1494	2020
Properties and behavior of carbon nanomaterials when interfacing neuronal cells: How far have we come? R Rauti, M Musto, S Bosi, M Prato, L Ballerini Carbon 143, 430-446	2019
Biomarkers for prostate cancer: prostate-specific antigen and beyond MJ Duffy Clinical Chemistry and Laboratory Medicine (CCLM) 58 (3), 326-339	2020
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... The Lancet 398 (10295), 131-142	2021
PTEN as a prognostic/predictive biomarker in cancer: an unfulfilled promise? C Bazzichetto, F Conciatori, M Pallocca, I Falcone, M Fanciulli, F Cognetti, ... Cancers 11 (4), 435	2019
Tumour metabolism and its unique properties in prostate adenocarcinoma DA Bader, SE McGuire Nature Reviews Urology 17 (4), 214-231	2020
Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications U Testa, G Castelli, E Pelosi Medicines 6 (3), 82	2019
Emerging role of PTEN loss in evasion of the immune response to tumours T Vidotto, CM Melo, E Castelli, M Koti, RB Dos Reis, JA Squire British journal of cancer 122 (12), 1732-1743	2020
Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway S Erdogan, K Turkekul, I Dibirdik, O Doganlar, ZB Doganlar, A Bilir, ... Biomedicine & Pharmacotherapy 107, 793-805	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。